Table 1

Prevention of breast cancer by GW7845 and tamoxifen

TreatmentaNo. of tumor-free rats/total no. of rats (P1; P2)bAverage no. of tumors (P1; P2)bATB (P1; P2)bRats with 3 or more tumors (P1; P2)bRats with tumor burden >5 g (P1; P2)b
Control (vehicle)5/422.45.622/4218/42
GW7845 Hi8/21 (0.02)1.1 (0.002)1.7 (0.002)2/21 (0.0009)1/21 (0.002)
GW7845 Lo7/21 (0.08)0.8 (<0.0001)1.5 (0.0004)0/21 (<0.0001)2/21 (0.009)
Tamoxifen5/331.6 (0.02)2.4 (0.02)7/33 (0.008)6/33 (0.03)
Tamoxifen + GW7845 Hi9/21 (0.009; 0.03)0.9 (0.0002; 0.03)0.9 (0.0002; 0.05)0/21 (<0.0001; 0.03)0/21 (0.0002)
Tamoxifen + GW7845 Lo12/21 (0.0003; 0.002)0.6 (<0.0001; 0.001)1.3 (0.0001; 0.01)1/21 (0.0002)3/21 (0.03)
  • a Doses used were as follows: 60 mg GW7845/kg diet (GW7845 Hi); 30 mg GW7845/kg diet (GW7845 Lo); and 0.5 mg tamoxifen/kg diet. All animals (21 days old) received an i.p. injection of 50 mg NMU/kg body weight 1 week before starting the feeding of chemopreventive agents.

  • b P1 is the value for the comparison of rats treated with chemopreventive agents with control rats treated with vehicle alone; P2 is the value for the comparison of rats treated with tamoxifen + GW7845 with rats treated with tamoxifen alone.